Monthly Archives: April 2013

Biogen IDEC, Inc. and Genentech, Inc. v. GlaxoSmithKline LLC et al.

Docket No. 2012-1120 DYK, PLAGER, REYNA April 16, 2013 Brief Summary: Claim term “anti-CD20 antibody” determined to refer to those antibodies “that bind to the same epitope of the CD20 antigen with similar affinity and specificity” as Rituxan® due to … Continue reading

Posted in Claim Construction | Leave a comment

Bayer Healthcare Pharmaceuticals, Inc. et al. v. Watson Pharmaceuticals, Inc. et al.

Docket No. 2012-1397, -1398, -1400 LOURIE, SCHALL, PROST April 16, 2013 Brief summary: Bayer’s claims relating to its contraceptive product YAZ® were found invalid for obviousness in view of several prior art references. Summary: Defendants appealed DC entry of SJ … Continue reading

Posted in Generics / ANDA, Obviousness | Leave a comment

In re Steve Morsa

Docket No. 2012-1609 RADER, LOURIE, O’MALLEY April 5, 2013 Brief summary: Applicant is not required to present affadavits or declarations to support non-enablement arguments relating to anticipation rejections (In re Antor Media Corp. only puts “the burden on the applicant … Continue reading

Posted in Anticipation (35 USC 102), Obviousness | Leave a comment

Checkpoint Systems, Inc. v. All-Tag Security S.A. et al.

Docket No. 2012-1085 NEWMAN, LOURIE, SCHALL March 25, 2013 Summary: Checkpoint appealed the jury finding that the case was “exceptional” under 35 USC § 285 and award of over $6 million in attorney fees, costs and interest to All Tag. … Continue reading

Posted in Attorney's Fees, Expert Testimony | Leave a comment